ErikRDubberkeMD

Infectious Disease • Saint Louis, MO

Assistant Professor, Internal Medicine, Washington University School of Medicine

Join to view full profile

Dr. Dubberke is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Dubberke's full profile

Already have an account?

Office
620 S Taylor Ave
# Dv
Saint Louis, MO 63110
Phone+1 314-362-9098

Fax+1 314-362-9851

Education & Training

Washington University/B-JH/SLCH ConsortiumFellowship, Infectious Disease, 2002 - 2004
Washington University/B-JH/SLCH ConsortiumResidency, Internal Medicine, 1999 - 2002
University of Illinois College of MedicineClass of 1999

Certifications & Licensure

MO State Medical License 2000 - 2025
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Infectious Disease

Clinical Trials

Autologous Fecal Therapy Start of enrollment: 2014 Mar 01
Completed
Phase 2
Fecal Microbiota Transplantation (FMT) for MDRO UTI Start of enrollment: 2018 Feb 08
Completed
Phase 1, Phase 2
TOX NEG Trial: Clostridium Difficile Diagnosis and Treatment Start of enrollment: 2017 Dec 29
Completed
Phase 4
Duvelisib to Combat COVID-19 Start of enrollment: 2020 Oct 12
Completed
Phase 2
Evaluating the Effect of NT-I7, a Long Acting Interleukin-7, to Increase Lymphocyte Counts and Enhance Immune Clearance of SARS-CoV-2 (COVID-19) Start of enrollment: 2021 Jul 31
Withdrawn
Phase 1
Join now to see all

Publications & Presentations

PubMed

A Retrospective Assessment of Guideline Adherence and Treatment Outcomes FromInfection Following the IDSA 2021 Clinical Guideline Update:Infection.
Erik R Dubberke, Qinghua Li, Engels N Obi, Vladimir Turzhitsky, Fakhar Siddiqui
Open Forum Infectious Diseases. 2024-10-01
CLOVER: A Phase 3 Randomized Trial Investigating the Efficacy and Safety of a Detoxified Toxin A/B Vaccine in Adults 50 Years and Older at Increased Risk of Clostridio...
Curtis J Donskey, Erik R Dubberke, Nicola P Klein, Elizabeth G Liles, Katarzyna Szymkowiak
Clinical Infectious Diseases. 2024-08-24
PUNCH CD3-OLS: a phase 3 prospective observational cohort study to evaluate the safety and efficacy of fecal microbiota, live-jslm (REBYOTA) in adults with recurrent C...
Paul Feuerstadt, Teena Chopra, Whitfield Knapple, Nicholas W Van Hise, Erik R Dubberke
Clinical Infectious Diseases. 2024-08-24

Press Mentions

Theriva Biologics Announces Presentation of Data from Cohort 1 of the Phase 1b/2a Clinical Trial of SYN-004 (Ribaxamase) in Allogeneic Hematopoietic Cell Transplant RecipientsApril 13th, 2023
Synthetic Biologics Reports Second Quarter 2019 Operational Highlights and Financial ResultsNovember 4th, 2019
Gut Makeup Could Make Diarrhea Less LikelyAugust 16th, 2019
Join now to see all

Grant Support

C. Difficile Disease In Stem Cell Transplant RecipientsNational Institute Of Allergy And Infectious Diseases2009–2011
Validation And Modeling Of A C. Difficile Infection Risk Prediction IndexNational Institute Of Nursing Research2009–2010